Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Breakthrough T1D-funded researcher wins Nobel Prize
Professor Baker’s Nobel Prize acknowledges his work in discovering a way to create new proteins that have never existed before. These proteins can potentially be used to treat conditions like type 1 diabetes (T1D).
Proteins are made up of various combinations of 20 different ‘building blocks’ called amino acids. In 2003, Professor Baker succeeded in using these building blocks to design a completely unique protein. Since then, his team of researchers have continued to create imaginative new proteins which can be used as medicines, vaccines, and tiny sensors.
In 2016, we recognised the potential application of this to T1D and awarded Professor Baker two grants, funding him to use a computer model to create new, glucose-responsive insulin (GRI). He designed a tiny glucose-responsive protein that can be added to existing long-acting forms of insulin to give them the ability to turn on at high glucose levels and off again once they are lowered.
GRIs are a type of novel (new) insulin, which can detect and respond to changing blood glucose levels, which could help relieve the burden of glucose monitoring. GRI is designed to be administered, lay waiting in the blood stream, and only be active when it is needed.
They are still at an early stage of development, but we’re funding researchers, like Professor Baker, to develop the next generation of insulins. Baker’s grant was one of many projects we are pursuing in GRI.
Through the Type 1 Diabetes Grand Challenge, our partnership with the Steve Morgan Foundation and Diabetes UK, we are investing £15 million in research to develop novel insulins. This includes GRIs, ultra-fast acting insulins, and any other new type of insulin that makes managing type 1 diabetes easier.
We are funding six researchers around the world to drive forward their novel insulin designs. Four of these researchers are developing GRIs, another is making a rapid acting insulin, and another is combining the hormones insulin and glucagon in one molecule.
These prestigious awards celebrate outstanding contributions in Peace, Literature, Physics, Chemistry, Physiology or Medicine, and Economic Sciences. The Prizes go to the best and brightest people with the most innovative and revolutionary ideas.
That this year’s Nobel Prize for Chemistry recognises a researcher and concept that we have previously funded demonstrates that we are funding some of the very best scientists in the world. Professor Baker shares this Prize with two other scientists who used artificial intelligence to work out the structure of proteins.
The 2024 Nobel Prize in Physiology or Medicine was awarded to two other researchers who have discovered microRNA, which regulates which genes are switched on. Breakthrough T1D is currently funding research into microRNA and its potential uses in T1D.
Learn more about the next generation of insulins, known as novel insulins.
Find out about our research to cure, treat and prevent type 1 diabetes.
Discover the research projects we are currently funding in the UK
Sana Biotechnology, a US-based biotech company, has released clinical data showing that the first person receiving engineered islets from deceased donors is now producing insulin without the need for immunosuppressive drugs.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
We’ve awarded four new grants to UK researchers to help improve lives and develop cures for people living with type 1 diabetes.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
